Business Description
Avenue Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US05360L3042
Description
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.8 | |||||
| 3-Year EPS without NRI Growth Rate | 33.3 | |||||
| 3-Year FCF Growth Rate | 38.2 | |||||
| 3-Year Book Growth Rate | -69.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.2 | |||||
| 9-Day RSI | 33.48 | |||||
| 14-Day RSI | 31.25 | |||||
| 6-1 Month Momentum % | -63.87 | |||||
| 12-1 Month Momentum % | -94.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.34 | |||||
| Quick Ratio | 2.34 | |||||
| Cash Ratio | 2.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -184.1 | |||||
| Shareholder Yield % | -130.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -227.61 | |||||
| ROIC % | -354.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-Forward-EBIT | -0.36 | |||||
| EV-to-FCF | -0.02 | |||||
| Price-to-Net-Current-Asset-Value | 0.69 | |||||
| Price-to-Net-Cash | 0.72 | |||||
| Earnings Yield (Greenblatt) % | 49444.4 | |||||
| FCF Yield % | -346.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avenue Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1092.66 | ||
| Beta | 0 | ||
| Volatility % | 71.17 | ||
| 14-Day RSI | 31.25 | ||
| 14-Day ATR (€) | 0.203734 | ||
| 20-Day SMA (€) | 3.3805 | ||
| 12-1 Month Momentum % | -94.67 | ||
| 52-Week Range (€) | 3.135 - 80.475 | ||
| Shares Outstanding (Mil) | 0.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avenue Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avenue Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avenue Therapeutics Inc Frequently Asked Questions
What is Avenue Therapeutics Inc(FRA:49Y)'s stock price today?
The current price of FRA:49Y is €3.20. The 52 week high of FRA:49Y is €80.47 and 52 week low is €3.14.
When is next earnings date of Avenue Therapeutics Inc(FRA:49Y)?
The next earnings date of Avenue Therapeutics Inc(FRA:49Y) is 2024-08-09 Est..
Does Avenue Therapeutics Inc(FRA:49Y) pay dividends? If so, how much?
Avenue Therapeutics Inc(FRA:49Y) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers